Compare Incyte Corporation (INCY) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Global X Uranium ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Global X Uranium ETF trades at $38.9 (market cap $5.48B). The key difference: Incyte Corporation is far larger — about 4.2× Global X Uranium ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Global X Uranium ETF for 62 Days on average.
| INCY | URA | |
|---|---|---|
Market Cap | $22.85B | $5.48B |
Volume | 1,927,029 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $129.93 | $61.81 |
52-Week Low | $83.80 | $37.52 |
Typical Hold Time | 33 Days | 62 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
URA (Global X Uranium ETF) trades at $38.90, down 2.58% with a bearish technical signal. The ETF faces pressure from recent uranium sector volatility despite positive long-term nuclear energy demand drivers. Key support levels cluster around $37-38 while resistance sits at $39-41. Recent news highlights both opportunities from AI power demand growth and risks from sector-specific headwinds.
The uranium sector faces near-term volatility but benefits from structural tailwinds including AI power demand and global nuclear expansion. Investment opportunities exist through diversified uranium exposure, though risks include commodity price sensitivity and regulatory uncertainty. Current technical weakness suggests cautious entry points may emerge near support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
